Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity

Massimo Mariotti, Renato Colognato, Marco Rimoldi, Manuela Rizzetto, Francesca Sisto, Valentina Coccè, Arianna Bonomi, Eugenio Parati, Giulio Alessandri, Renzo Bagnati, Augusto Pessina

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To improve the drug delivery efficiency on target cells, many strategies have been developed including Mesenchymal Stromal Cells (MSCs) approaches. In a previous study, we found that bone-marrow-derived MSCs (BM-MSCs) were able to incorporate and release the anti-tumor and anti-angiogenic drug, Paclitaxel (PTX). In this study, we evaluated the stability of PTX in standard cell culture conditions by analyzing the metabolites produced by MSCs after their incorporation of the drug. We are able to show that MSCs do not release either 3-OH-PTX or 6-OH-PTX metabolites (having a lower anticancer activity) but release an active PTX molecule together with the isomer 7-Epitaxol, is known to maintain the whole biological activity. This confirms that the simple procedure of MSCs priming with a drug (without any genetic cell manipulation), in our case PTX, does not modify the activity of the molecule and provides a new biological-device to carry and deliver PTX in tumor sites, by contributing to improve drug efficacy and target selectivity in cancer therapy.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume15
Issue number3
Publication statusPublished - 2015

Fingerprint

Paclitaxel
Mesenchymal Stromal Cells
Pharmaceutical Preparations
Neoplasms
Angiogenesis Inhibitors
Cell Culture Techniques
Bone Marrow
Equipment and Supplies

Keywords

  • Anti-tumor activity
  • Cancer
  • Drug delivery
  • Mesenchymal stromal cell
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Mariotti, M., Colognato, R., Rimoldi, M., Rizzetto, M., Sisto, F., Coccè, V., ... Pessina, A. (2015). Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity. Anti-Cancer Agents in Medicinal Chemistry, 15(3), 400-405.

Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity. / Mariotti, Massimo; Colognato, Renato; Rimoldi, Marco; Rizzetto, Manuela; Sisto, Francesca; Coccè, Valentina; Bonomi, Arianna; Parati, Eugenio; Alessandri, Giulio; Bagnati, Renzo; Pessina, Augusto.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 15, No. 3, 2015, p. 400-405.

Research output: Contribution to journalArticle

Mariotti, M, Colognato, R, Rimoldi, M, Rizzetto, M, Sisto, F, Coccè, V, Bonomi, A, Parati, E, Alessandri, G, Bagnati, R & Pessina, A 2015, 'Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity', Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 3, pp. 400-405.
Mariotti, Massimo ; Colognato, Renato ; Rimoldi, Marco ; Rizzetto, Manuela ; Sisto, Francesca ; Coccè, Valentina ; Bonomi, Arianna ; Parati, Eugenio ; Alessandri, Giulio ; Bagnati, Renzo ; Pessina, Augusto. / Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity. In: Anti-Cancer Agents in Medicinal Chemistry. 2015 ; Vol. 15, No. 3. pp. 400-405.
@article{df18a65a9bff45699d21d8366cdec630,
title = "Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity",
abstract = "To improve the drug delivery efficiency on target cells, many strategies have been developed including Mesenchymal Stromal Cells (MSCs) approaches. In a previous study, we found that bone-marrow-derived MSCs (BM-MSCs) were able to incorporate and release the anti-tumor and anti-angiogenic drug, Paclitaxel (PTX). In this study, we evaluated the stability of PTX in standard cell culture conditions by analyzing the metabolites produced by MSCs after their incorporation of the drug. We are able to show that MSCs do not release either 3-OH-PTX or 6-OH-PTX metabolites (having a lower anticancer activity) but release an active PTX molecule together with the isomer 7-Epitaxol, is known to maintain the whole biological activity. This confirms that the simple procedure of MSCs priming with a drug (without any genetic cell manipulation), in our case PTX, does not modify the activity of the molecule and provides a new biological-device to carry and deliver PTX in tumor sites, by contributing to improve drug efficacy and target selectivity in cancer therapy.",
keywords = "Anti-tumor activity, Cancer, Drug delivery, Mesenchymal stromal cell, Paclitaxel",
author = "Massimo Mariotti and Renato Colognato and Marco Rimoldi and Manuela Rizzetto and Francesca Sisto and Valentina Cocc{\`e} and Arianna Bonomi and Eugenio Parati and Giulio Alessandri and Renzo Bagnati and Augusto Pessina",
year = "2015",
language = "English",
volume = "15",
pages = "400--405",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity

AU - Mariotti, Massimo

AU - Colognato, Renato

AU - Rimoldi, Marco

AU - Rizzetto, Manuela

AU - Sisto, Francesca

AU - Coccè, Valentina

AU - Bonomi, Arianna

AU - Parati, Eugenio

AU - Alessandri, Giulio

AU - Bagnati, Renzo

AU - Pessina, Augusto

PY - 2015

Y1 - 2015

N2 - To improve the drug delivery efficiency on target cells, many strategies have been developed including Mesenchymal Stromal Cells (MSCs) approaches. In a previous study, we found that bone-marrow-derived MSCs (BM-MSCs) were able to incorporate and release the anti-tumor and anti-angiogenic drug, Paclitaxel (PTX). In this study, we evaluated the stability of PTX in standard cell culture conditions by analyzing the metabolites produced by MSCs after their incorporation of the drug. We are able to show that MSCs do not release either 3-OH-PTX or 6-OH-PTX metabolites (having a lower anticancer activity) but release an active PTX molecule together with the isomer 7-Epitaxol, is known to maintain the whole biological activity. This confirms that the simple procedure of MSCs priming with a drug (without any genetic cell manipulation), in our case PTX, does not modify the activity of the molecule and provides a new biological-device to carry and deliver PTX in tumor sites, by contributing to improve drug efficacy and target selectivity in cancer therapy.

AB - To improve the drug delivery efficiency on target cells, many strategies have been developed including Mesenchymal Stromal Cells (MSCs) approaches. In a previous study, we found that bone-marrow-derived MSCs (BM-MSCs) were able to incorporate and release the anti-tumor and anti-angiogenic drug, Paclitaxel (PTX). In this study, we evaluated the stability of PTX in standard cell culture conditions by analyzing the metabolites produced by MSCs after their incorporation of the drug. We are able to show that MSCs do not release either 3-OH-PTX or 6-OH-PTX metabolites (having a lower anticancer activity) but release an active PTX molecule together with the isomer 7-Epitaxol, is known to maintain the whole biological activity. This confirms that the simple procedure of MSCs priming with a drug (without any genetic cell manipulation), in our case PTX, does not modify the activity of the molecule and provides a new biological-device to carry and deliver PTX in tumor sites, by contributing to improve drug efficacy and target selectivity in cancer therapy.

KW - Anti-tumor activity

KW - Cancer

KW - Drug delivery

KW - Mesenchymal stromal cell

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=84930912569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930912569&partnerID=8YFLogxK

M3 - Article

C2 - 24942547

AN - SCOPUS:84930912569

VL - 15

SP - 400

EP - 405

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 3

ER -